Introduction
Ribavirin is a broad-spectrum antiviral agent that is active against a number of viruses, including hepatitis C virus (HCV) (1) (2) (3) (4) (5) (6) . In combination with pegylated interferon, ribavirin is an established treatment for chronic HCV infection (7, 8) , and more recently has also become a component of protease inhibitor-based triple therapy regimens with boceprevir or telaprevir (9) (10) (11) (12) .
Ribavirin is contraindicated in patients with creatinine clearance < 50 mL/min (13) . Pharmacokinetic studies in healthy volunteers and patients with HCV infection indicate that although both renal and hepatic pathways contribute to ribavirin elimination, the relative contribution of renal pathways is comparatively low, accounting for only 5-15% of the total elimination (14) (15) (16) (17) (18) (19) . It is therefore somewhat surprising that ribavirin has been shown to accumulate in patients with renal failure (20, 21) . A recent pharmacokinetic study of single-dose oral ribavirin in patients with renal dysfunction highlighted substantial alterations in ribavirin pharmacokinetics associated with declining renal function (22) . The authors proposed that changes in ribavirin metabolism associated with renal impairment might underlie the altered pharmacokinetics seen in this patient group. The objective of the present study was to compare ribavirin pharmacokinetics after single oral and intravenous (IV) doses in patients with renal dysfunction, to further evaluate mechanisms contributing to the altered pharmacokinetics.
Materials and Methods
This was an open-label, parallel-group, single-dose, and 2-stage study. The first stage was designed to assess the pharmacokinetic properties of a single oral 400-mg dose of ribavirin, whereas the second stage assessed the pharmacokinetics of a single 400-mg IV dose, in subjects with varying degrees of stable chronic renal insuffi ciency. Subjects who had received oral ribavirin during the first stage of the study and who continued to meet the enrollment criteria were permitted to enroll in the second phase of the study. The two stages of the study were separated by a washout period of several months. The study was conducted in accordance with the Principles of Good Clinical Practice and the Declaration of Helsinki. All subjects provided written informed consent to participate in this study, and the protocol was approved by the Research Consultants Review Committee, Austin, Texas.
Study population
Male and female subjects, 18 to 65 years of age, who had normal renal function or varying degrees of stable chronic renal insufficiency were enrolled. Subjects with normal renal function (creatinine clearance [CL cr ] > 90 mL/min) were excluded if they had a history of cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, respiratory, hepatic, or renal disease, or any other disorder requiring physician care. Subjects with evidence of HIV or hepatitis B coinfection, or urinary traces of drugs of abuse, were also excluded. Subjects with compromised renal function (CL cr < 90 mL/min) were excluded if they had significant medical disorders unrelated to their renal disorder that would substantially interfere with their ability to participate in the study. (severe renal dysfunction). During stage 2, participants again fasted overnight and then received a single IV 400-mg dose of ribavirin solution (13.3 mL of 30 mg/mL solution), infused over 15 min (0.89 mL/min) using a syringe pump. For analysis, participants were again divided into groups I to IV as described for stage 1. Participants continued fasting until 4 hours after the dose and were discharged from the study center after 48 h. Subsequent samples were collected on an outpatient basis.
Study design

Sample collection and assay for pharmacokinetic assessments
After oral dosing, blood samples for determination of plasma ribavirin concentrations were obtained immediately prior to drug administration and then at specifi ed time intervals until 168 h after the dose. After IV infusion dosing, additional blood samples were collected at 0.08, 0.16, 0.25, and 0.5 h after the dose and then again at the same time intervals as for the oral dose until 168 h after the dose. After collection, the plasma was separated from blood samples and frozen at -80°C until analysis.
Block urine samples were collected immediately prior to drug administration and at 12-to 24-h intervals until 168 h following the dose. Plasma and urine concentrations of ribavirin were determined using high-performance liquid chromatography/tandem mass spectrometry, as previously described (22).
Pharmacokinetic analysis
Plasma and urine ribavirin concentrations above the limit of quantitation (plasma, 50 ng/mL; urine, 250 ng/mL) were used to calculate pharmacokinetic parameters using model-independent methods (23) . The maximum plasma concentration (C max ) and time to maximum plasma concentration (T max ) were the observed values. The area under the plasma concentration-time curve from time zero to the time of the final quantifiable sample (AUC tf ) was calculated using the linear trapezoidal method. Individual terminal rate constants could not be determined with precision; therefore, the elimination half-life (t ½ ) and area under the plasma concentrationtime curve from time zero to infinity (AUC I ) were not reported. Pharmacokinetic analysis was consequently limited to estimation of individual AUC tf value instead of AUC I . Total plasma clearance (CL) was calculated by dividing the dose by AUC tf after IV dosing. Renal clearance (CL r ) was calculated by dividing the amount excreted (A e ) in the urine from time 0 to 168 h by the AUC tf . Nonrenal clearance (CL nr ) was the difference between CL and CL r .
Absolute bioavailability (F) was calculated (as percentage) for each subject as [AUC PO 
, where tf, po was the tf for that subject following oral administration, and AUC PO (tf, po) and AUC IV (tf, po) were AUC values from time zero to tf, for po dose following administration of oral and IV doses to the same subjects, respectively. Absolute bioavailability (F) was expressed as a percentage and was not calculated from urine data, because most subjects had renal impairment and could not provide adequate urine samples. kinetic parameters of each group. Linear regression analyses were used to determine the relationship between CL cr and CL r , Vd ss , and F.
Results
Patient characteristics
All 14 subjects enrolled received single oral and IV doses of ribavirin (Table 1) . Data from all subjects were included in the pharmacokinetic analyses and in evaluations of safety and tolerability.
Pharmacokinetic assessment
After a single oral dose of ribavirin, mean AUC tf increased with the severity of renal dysfunction; however, there was no notable change in C max associated with declining renal function ( Table 2) . After a single IV dose of ribavirin, mean C max values (at end of ribavirin infusion) were similar in groups I, II, and IV, and slightly higher in group III. In contrast, renal dysfunction was associated with a corresponding increase in mean AUC tf of 1.3-, 2.0-, and 2.0-fold in The volume of distribution at steady state (Vd ss ) was calculated using the following equation: (CL) × MRT tf  CL × 1/2 (infusion duration), where MRT tf was the mean residence time obtained from the ratio of area under the fi rst moment curve from time zero to tf (AUMC tf ) and AUC tf . CL r was calculated by dividing A e in urine over 168 h after IV dosing by AUC tf .
Safety
Safety was assessed based on the results of vital signs, which were measured at screening, immediately prior to dosing (0 h), and then at regular intervals until 168 h following the dose. Electrocardiograms and laboratory assessments were obtained at screening and 168 h after dosing. The intensity (severity) of adverse events was assessed according to the Common Toxicity Criteria (CTC) grading system where applicable, or graded as mild, moderate, severe, or life threatening as defi ned in the protocol.
Statistical analyses
Summary statistics were determined for the pharmaco- Table 1 . Demographic and baseline characteristics of study participants In patients receiving IV ribavirin, mean CL decreased as CL cr declined (mean CL relative to controls was 80%, 57%, and 51% in groups II, III, and IV, respectively). Regression of CL against CL cr was highly statistically signifi cant (CL = 102 + 1.81  CL cr ; r 2 = 0.64, p < 0.001).
In subjects with normal renal function receiving IV ribavirin, mean ribavirin CL r was ~36% of CL (107 mL/min vs. 296 mL/min). Ribavirin CL r declined with decreasing renal function (Figure 1) . Regression of CL r against CL cr was highly statistically significant (CL r = −13.1 + 0.99 × CL cr ; r 2 = 0.88, p < 0.001). Ribavirin CL nr also tended to decline with decreased renal function. Compared with control subjects with normal renal function, the degree of decline in mean CL r was greater in groups II, III, and IV (54%, 23%, and 10%, respectively) than that in mean CL nr (94%, 76%, and 75%).
Following IV administration, ribavirin Vd ss also declined with decreasing renal function. Regression of Vd ss against CL cr was statistically significant (Vd ss = 414 + 2.55 × CL cr ; r 2 = 0.38, p < 0.02). Absolute bioavailability following oral administration was 35%, 60%, 57%, and 71% for groups I-IV, respectively. Although absolute bioavailability tended to increase with renal dysfunction, regression of bioavailability (%F) against CL cr was not statistically signifi cant (p = 0.12).
Safety
R i b a v i r i n w a s s a f e a n d w e l l t o l e r a t e d w h e n administered as a single oral or IV dose of 400 mg to subjects with renal dysfunction. Eight adverse events of mild to moderate intensity were reported, the most common being headache (n = 3), with individual reports of allergy, hyperglycemia, hypoglycemia, pharyngitis, and thrombocytopenia. Apart from the expected laboratory test abnormalities in subjects with renal dysfunction, there were no changes of clinical relevance noted during this study.
Discussion
Ribavirin is eliminated by both renal and hepatic routes, with gastrointestinal metabolism accounting for the majority of fi rst-pass elimination of the parent molecule (24) . Although renal excretion accounts for only 5-15% of the total elimination (24), the results of the present study show that the pharmacokinetic properties of ribavirin are significantly altered in subjects with renal dysfunction compared with subjects with normal renal function. We found that ribavirin AUC and C max values were increased, and CL, CL r , CL nr , Vd ss , and A e values were reduced in subjects with renal dysfunction compared with controls with normal renal function. The magnitude of these changes increased with the severity of renal dysfunction. We have identified 4 possible mechanisms for the altered pharmacokinetics of ribavirin in subjects with renal dysfunction; these are discussed in the text that follows.
Reduction of renal clearance in absolute and proportional terms
In the present study, mean CL r after IV dosing in control subjects was 36%, which is similar to previously reported results (16) . Mean CL r was 54%, 23%, and 10% relative to subjects with normal renal function in groups II, III, and IV, respectively. In these subjects, the proportion of total CL accounted for by CL r after IV dosing declined as renal function decreased (25%, 15%, and 7%, in groups II, III, and IV, respectively).
Mean CL r after oral dosing was 56%, 28%, and 9% compared with controls in groups II, III, and IV, respectively; these values are very similar to those observed after IV dosing. In contrast, in these subjects, the proportion of total CL accounted for by CL r after oral dosing declined as renal function decreased (14%, 9%, and 5% in groups II, III, and IV, respectively).
Thus, CL r as a proportion of total CL was always greater after IV dosing compared with oral dosing, both in controls and in subjects with renal dysfunction. This could refl ect a reduction in fi rst-pass metabolism, which is substantial after oral dosing (~50%) (24) . Also, the ratio of oral CL r :IV CL r was smallest for subjects with normal renal function (0.42) and was progressively greater as renal function declined (0.56, 0.60, and 0.71 for groups II, III, and IV, respectively). One interpretation of this fi nding is that the proportion of ribavirin cleared by fi rst-pass metabolism decreases as renal function declines. This would be consistent with the fi nding that CL nr was reduced and F increased as renal function declined (as follows). 
Reduced non-renal clearance in absolute terms
In addition to changes in CL r , CL nr also decreased as renal function declined. Compared with controls, mean CL nr was 94%, 76%, and 75% in groups II, III, and IV, respectively, after IV dosing. After oral dosing, mean CL nr relative to controls was 54%, 48%, and 27% in groups II, III, and IV, respectively. In a separate study in patients with hepatic dysfunction, there were no changes in single-dose pharmacokinetic parameters in patients with hepatic dysfunction compared with controls (17) . Thus, the changes in CL nr in the present study may indicate a significant effect of renal dysfunction on nonhepatic sites of ribavirin metabolism. Although the mechanisms underlying changes in nonrenal clearance in subjects with renal dysfunction are poorly understood, this is a common fi nding with many drugs (25, 26) .
Increased absolute bioavailability
A third possible mechanism is that the higher exposures noted in patients with renal dysfunction could be due to increased absolute bioavailability (F). The present study showed that CL r as a proportion of total CL was always higher after IV dosing compared with oral dosing, both in control subjects and in patients with renal dysfunction, reflecting the absence of a firstpass metabolism. As previously mentioned, the ratio of oral CL r to IV CL r was lowest for subjects with normal renal function and became progressively greater as renal function declined, which may be evidence that the proportion of ribavirin being cleared by first-pass metabolism decreased as renal function declined. This would also be consistent with the reduction in CL nr described earlier. Ribavirin is almost entirely absorbed after oral administration, but undergoes signifi cant fi rstpass metabolism, and absolute bioavailability is ~50% (24) . The enzymes responsible for this process and their localization have not yet been identifi ed; however, the site of metabolism is cytosolic and not ribosomal. Hydrolysis to form the carboxamide metabolite is one of the main metabolic pathways for ribavirin (27) , and hydrolysis reactions are reportedly reduced in chronic renal failure (28) . Increased absolute bioavailability has been reported in patients with renal dysfunction for a number of other drugs (26, (29) (30) (31) , including metoclopramide, erythromycin, propranolol, and other β-blockers.
Reduced volume of distribution
A fourth possible mechanism is that ribavirin Vd is affected by renal dysfunction. In the present study, ribavirin Vd ss declined with decreasing renal function after IV administration, and regression of Vd ss against CLcr was statistically significant. Elimination-phase profiles and t ½ values after oral administration were similar in patients with declining renal function (in groups II, III, and IV); however, the Vd after oral administration was not determined.
Notable similarities exist between the findings of the present study and the impact of renal impairment on the pharmacokinetics of another purine nucleoside analogue, didanosine (32) . Both didanosine and ribavirin are substrates for the N1 nucleoside transporter. Renal clearance accounts for ~50% of the total clearance of didanosine in subjects with normal renal function; however, didanosine AUC was increased 4-to 5-fold in patients with end-stage renal disease (32) . Renal impairment was associated with reductions in didanosine CLr, CLnr, and Vd, but had no effect on absolute bioavailability (32) . The authors concluded that the changes in didanosine pharmacokinetics observed in patients with renal impairment may be due to altered metabolism of didanosine associated with renal failure.
In the present study, single 400-mg oral and IV doses of ribavirin were generally safe and well tolerated in healthy volunteers with normal renal function and in patients with renal insufficiency. The most commonly reported adverse event, headache, has been reported previously following single-and multiple-dose administration of ribavirin (15) , and no serious drugrelated adverse events were reported.
A possible shortcoming of this study should be acknowledged. Although a relatively small numbers of subjects were enrolled, the pharmacokinetic parameters for each group were similar to those previously reported (21, 22) , and in many analyses renal function was evaluated as a continuous variable.
The present study has identifi ed a number of possible mechanisms (changes in CL r and CL nr , increased bioavailability, and altered Vd) that might account for the altered single-dose pharmacokinetic profile of ribavirin in patients with renal dysfunction. As ribavirin has a well-established exposure-toxicity profi le, it is important to ensure that patients with renal dysfunction are dosed appropriately to avoid excessive hemolysis. Because of the extensive accumulation that occurs with multipledose ribavirin pharmacokinetics, this single-dose study cannot provide defi nitive dosing guidelines for patients with renal impairment (15, 24) . Furthermore, patients with chronic renal dysfunction also appear more likely to develop ribavirin-induced anemia than do control subjects. In addition to ribavirin-induced hemolysis, other factors that may affect ribavirin dosing include inadequate marrow responsiveness to anemia as well as reduced erythrocyte longevity due to uremia.
In conclusion, this study has identified a number of mechanisms to explain the alterations in ribavirin pharmacokinetics in subjects with stable chronic renal impairment, generally similar to those reported previously for didanosine.
